TY - JOUR
T1 - Immunoprophylaxis to Prevent Mother-to-Child Transmission of HIV-1
AU - Safrit, Jeffrey T.
AU - Ruprecht, Ruth
AU - Ferrantelli, Flavia
AU - Xu, Weidong
AU - Kitabwalla, Moiz
AU - Van Rompay, Koen
AU - Marthas, Marta
AU - Haigwood, Nancy
AU - Mascola, John R.
AU - Luzuriaga, Katherine
AU - Jones, Samuel Adeniyi
AU - Mathieson, Bonnie J.
AU - Newell, Marie Louise
PY - 2004/2/1
Y1 - 2004/2/1
N2 - Antiretroviral therapy can profoundly reduce the risk of mother-to-child transmission (MTCT) of HIV, but the drugs have a relatively short half-life and should thus be administered throughout breast-feeding to optimally prevent postnatal infection of the infant. The potential toxicities and the development of resistance may limit the long-term efficacy of antiretroviral prophylaxis, and a safe and effective active/passive immunoprophylaxis regimen, begun at birth, and potentially overlapping with interpartum or neonatal chemoprophylaxis, would pose an attractive alternative. This review draws on data presented at the Ghent Workshop on prevention of breast milk transmission and on selected issues from a workshop specifically relating to immunoprophylaxis held in Seattle in October 2002. This purpose of this review is to address the scientific rationale for the development of passive (antibody) and active (vaccine) immunization strategies for prevention of MTCT. Data regarding currently or imminently available passive and active immunoprophylaxis products are reviewed for their potential use in neonatal trials within the coming 1-2 years.
AB - Antiretroviral therapy can profoundly reduce the risk of mother-to-child transmission (MTCT) of HIV, but the drugs have a relatively short half-life and should thus be administered throughout breast-feeding to optimally prevent postnatal infection of the infant. The potential toxicities and the development of resistance may limit the long-term efficacy of antiretroviral prophylaxis, and a safe and effective active/passive immunoprophylaxis regimen, begun at birth, and potentially overlapping with interpartum or neonatal chemoprophylaxis, would pose an attractive alternative. This review draws on data presented at the Ghent Workshop on prevention of breast milk transmission and on selected issues from a workshop specifically relating to immunoprophylaxis held in Seattle in October 2002. This purpose of this review is to address the scientific rationale for the development of passive (antibody) and active (vaccine) immunization strategies for prevention of MTCT. Data regarding currently or imminently available passive and active immunoprophylaxis products are reviewed for their potential use in neonatal trials within the coming 1-2 years.
KW - Immunoprophylaxis
KW - Neonates
KW - Prevention mother-to-child transmission
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=9144262305&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9144262305&partnerID=8YFLogxK
U2 - 10.1097/00126334-200402010-00012
DO - 10.1097/00126334-200402010-00012
M3 - Review article
C2 - 14722451
AN - SCOPUS:9144262305
SN - 1525-4135
VL - 35
SP - 169
EP - 177
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 2
ER -